SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosaki

ACRS

Related stories